Revenue for the quarter rose 32.8% year-on-year to ₹1,003.4 crore from ₹755.6 crore, marking the company’s first quarterly revenue above ₹1,000 crore. While revenue grew 6.5% sequentially. Dollar revenue increased 25.6% from a year earlier to $109.7 million.
EBITDA increased 10.9% to ₹163.6 crore in the March quarter, compared with ₹147.5 crore in the corresponding period last year. EBITDA margin stood at 16.3% in the quarter, compared with 19.5% in the year-ago period.
Also Read: Indegene CFO Suhas Prabhu says margins fell due to one-time M&A costs, expects recovery soon
Adjusted EBITDA for the quarter stood at ₹188.9 crore, up 23.2% year-on-year and 5.4% sequentially. Adjusted EBITDA margin came in at 18.8% in the fourth quarter.
The company also reported a strong bookings performance in the quarter, securing one deal with an annual contract value (ACV) of over $3 million and seven deals in the $1–3 million range.
For the full year FY26, Indegene reported revenue of ₹3,510.5 crore, up 23.6% year-on-year, crossing the ₹3,500 crore annual revenue milestone. In dollar terms, full-year revenue rose 18.2% to $396.9 million. Adjusted EBITDA for FY26 stood at ₹679.3 crore, up 20.8% year-on-year, with a margin at 19.4%.
Also Read: Indegene Q3 results: Revenue surges 31% to ₹942 crore but profit, margins dip
Cash flow from operations for the year rose 47.3% year-on-year to ₹650.8 crore, reflecting stronger operating performance and business fundamentals.
The board of directors has recommended a final dividend of ₹2.25 per equity share of face value ₹2 each for the financial year ended March 31, 2026. The proposed final dividend will be paid within 30 days of shareholder approval at the upcoming annual general meeting. The record date for determining eligible shareholders and the date of the AGM will be announced separately.
Manish Gupta, Chairman and CEO, Indegene, said, “FY26 was a landmark year for Indegene. We surpassed ₹1,000 crore in quarterly revenue for the first time, and ₹3,500 crore for the full year.
Also Read: Indegene Q1 net profit climbs 33% on higher revenue, margins
This reflects growing strategic depth in our largest client relationships, with 53 clients contributing over $1M in annual revenue, alongside breakthrough GenAI-led wins across Commercial and Medical. With a strong pipeline and an industry-leading revenue per employee of $75k, we will build on this momentum in FY27.”
Shares of Indegene Ltd ended at ₹497.70, down by ₹2.05, or 0.41%, on the BSE.
